Scarica l'app Stockscreener
17.53
0.46%
0.08
Dopo l'orario di chiusura:
17.53
Eton Pharmaceuticals Inc Borsa (ETON) Ultime notizie
HC Wainwright Issues Pessimistic Outlook for ETON Earnings - MarketBeat
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Date and Conference Call Details - Quiver Quantitative
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, ... - Bluefield Daily Telegraph
Eton inks deal to sell its 10th rare disease drug - Crain's Chicago Business
Craig Hallum Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price - MarketBeat
Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum - TipRanks
Eton Pharmaceuticals acquires U.S. rights to hemangioma drug By Investing.com - Investing.com Canada
Eton Pharmaceuticals Acquires US Commercialization Rights to Pierre Fabre's Hemangeol - marketscreener.com
HC Wainwright Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock - MarketBeat
Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL - TipRanks
Eton Pharmaceuticals, Inc. announced that, in addition to the acquisition of core assets, the company also plans to purchase approximately $1.5 million worth of inventory products at the time of transaction closing. - Bitget
Understanding Momentum Shifts in (ETON) - Stock Traders Daily
Lumbard & Kellner LLC Buys New Holdings in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution - Benzinga
Only FDA-approved infantile hemangioma drug moves to Eton with $0 co-pays - Stock Titan
Eton Pharmaceuticals (NASDAQ: ETON) licenses U.S. HEMANGEOL rights in orphan drug deal - Stock Titan
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution - Sahm
Eton Pharmaceuticals' DESMODA Receives FDA Approval - Intellectia AI
US FDA approves Eton Pharma’s hormonal disorder drug - 1470 & 100.3 WMBD
Eton Pharmaceuticals Receives FDA Approval for New Drug Launch - Intellectia AI
Eton Reports US FDA Approval for Desmoda Oral Solution - marketscreener.com
Eton Pharmaceuticals Wins FDA Approval for DESMODA Therapy - TipRanks
Eton wins FDA nod for rare disorder therapy Desmoda (ETON) - Seeking Alpha
US FDA approves Eton's liquid therapy for rare water-balance disorder - Reuters
US FDA approves Eton Pharma's hormonal disorder drug - AOL.com
Eton Pharmaceuticals Launches DESMODA™, First FDA-Approved Oral Solution for Central Diabetes Insipidus - Quiver Quantitative
FDA clears first liquid desmopressin for rare water-balance disorder - Stock Titan
US FDA approves Eton’s liquid therapy for rare water-balance disorder - whbl.com
ETON Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
FDA To Decide On ET-600 On February 25: Will It Mark Eton's Ninth Commercial Product? - RTTNews
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th - The Manila Times
Rare-disease drug maker Eton to meet attendees at Leerink conference - Stock Titan
February 2026's Top Growth Companies With Insider Influence - simplywall.st
Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment - MSN
What are Eton Pharmaceuticals Inc.’s technical support levelsJuly 2025 Big Picture & Real-Time Stock Entry Alerts - mfd.ru
Volatility Watch: Is Eton Pharmaceuticals Inc a cyclical or defensive stockGap Up & Safe Entry Zone Identification - baoquankhu1.vn
Activity Recap: Is Eton Pharmaceuticals Inc. still a buy after recent gains - mfd.ru
Eton Pharmaceuticals (ETON) Investor Outlook: A Small-Cap Biotech with a 78.68% Potential Upside - DirectorsTalk Interviews
What drives Eton Pharmaceuticals Inc.’s stock priceEarnings Miss & Weekly High Potential Stock Alerts - mfd.ru
We Might See A Profit From Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Soon - simplywall.st
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of "Hold" by Analysts - MarketBeat
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Hold” by Analysts - Defense World
Analysts Are Bullish on These Healthcare Stocks: Eton Pharmaceuticals (ETON), HealthStream (HSTM) - The Globe and Mail
Eton Pharmaceuticals stock rises after licensing ultra-rare disease drug By Investing.com - Investing.com South Africa
Eton Pharmaceuticals stock rises after licensing ultra-rare disease drug - Investing.com India
Eton Pharmaceuticals Licenses US Marketing Rights to Ultra-Rare Disease Product - marketscreener.com
Eton Pharmaceuticals licenses ultra-rare disease treatment candidate - Investing.com
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate - The Manila Times
Eton Pharmaceuticals licenses ultra-rare disease treatment candidate By Investing.com - Investing.com UK
Eton Pharmaceuticals Licenses U.S. Marketing Rights for Ultra-Rare Disease Product Candidate, Anticipates FDA Approval by Mid-2026 - Quiver Quantitative
Aug Drivers: What drives Eton Pharmaceuticals Incs stock priceJuly 2025 Macro Moves & Real-Time Volume Analysis - baoquankhu1.vn
Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Unraveling the 96.72% Potential Upside for Investors - DirectorsTalk Interviews
Breakout Zone: Is Eton Pharmaceuticals Inc a defensive stockQuarterly Growth Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Eton Pharmaceuticals, Inc. (ETON) Investor Outlook: Unpacking The 96% Upside Potential - DirectorsTalk Interviews
Eton Pharmaceuticals: An Undervalued Small Cap With High Growth (NASDAQ:ETON) - Seeking Alpha
Geopolitics Watch: Can Eton Pharmaceuticals Inc maintain sales growthWatch List & Low Risk High Reward Ideas - baoquankhu1.vn
0.21%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):